Latest market price
45.69
-0.32-0.70%
BSXQT36Boston Scientific Corporation·NYSE
45.69-0.70%
Earnings
Down 0.7% — Earnings due 2026-10-28 — pre-report positioning.
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500P/E18.57EPS (ttm)2.46Insider Own0.20%Shs Outstand1.45BPerf Week2.93%
Market Cap66.22BForward P/E13.53EPS next Y3.38Insider Trans7.25%Shs Float1.44BPerf Month2.26%
Enterprise Value78.30BPEG2.14EPS next Q-Inst Own56.36%Short Float2.87%Perf Quarter0.40%
Income3.67BP/S3.15EPS this Y6.64%Inst Trans0.00%Short Ratio2.08Perf Half Y-26.39%
Sales21.00BP/B2.63EPS next Y4.32%ROA8.11%Short Interest41.41MPerf YTD-52.08%
Book/sh17.37P/C122.86EPS next 5Y8.68%ROE14.90%52W High105.64 -56.75%Perf Year-56.00%
Cash/sh0.37P/FCF18.27EPS past 3/5Y63.25% -ROIC10.57%52W Low41.39 10.39%Perf 3Y-9.90%
Dividend Est.-EV/EBITDA13.49Sales past 3/5Y16.54% 15.16%Gross Margin71.16%Volatility2.73% 2.57%Perf 5Y5.28%
Dividend TTM-EV/Sales3.73EPS Y/Y TTM96.80%Oper. Margin21.46%ATR (14)1.26Perf 10Y97.37%
Dividend Ex-Date-Quick Ratio0.74Sales Y/Y TTM25.37%Profit Margin17.47%RSI (14)57.22Recom2.14
Dividend Gr. 3/5Y-Current Ratio1.24EPS Q/Q14.67%SMA204.56%Beta0.59Target Price59.55
Payout0.00%Debt/Eq0.51Sales Q/Q7.53%SMA500.33%Rel Volume0.45Prev Close46.01
Employees59,000LT Debt/Eq0.49EarningsOct 28SMA200-20.99%Avg Volume19.46MPrice45.69
IPO DateMay 19, 1992Option/ShortYes / YesEPS/Sales Surpr.2.93% 1.25%Net Debt/EBITDA2.08Volume8,769,837Change-0.70%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-14-26ReiteratedTruist SecuritiesBuy$62 → $51
Oct-13-26ReiteratedMizuho SecuritiesOutperform$60 → $55
Oct-06-26InitiatedBarclaysEqual Weight$89 → $48
Oct-03-26ReiteratedBernsteinOutperform$60 → $54
Sep-21-26ReiteratedOppenheimerOutperform$85 → $65
Sep-17-26DowngradeCitigroupBuy → Neutral
Sep-09-26ReiteratedBTIGBuy$60 → $56
Jul-31-26DowngradeArgus ResearchBuy → Hold
Jul-30-26ReiteratedDeutsche BankHold$75 → $60
Jul-30-26ReiteratedRobert W. Baird$64 → $56
Latest News· Times ET
Oct-23-26
Oct-22-26
Oct-21-26
Oct-20-26
Oct-17-26
Oct-16-26
Oct-15-26
Oct-14-26
Oct-13-26
Company

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Ownership
Total institutional ownership56.36%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue20,99620,07416,747——————
Cost of Goods Sold Incl. D&A6,0556,2216,480——————
Gross Profit14,94013,85310,267——————
Selling, General and Administrative Excl. Other7,1596,8875,984——————
Research and Development2,1532,0521,615——————
Other Operating Expense1,12294333——————
Operating Income4,5063,9712,635——————
Interest Expense363349387——————
Unusual Expense
—————————
Non-Operating Income (Expense)-282-23734——————
Net Income Before Taxes3,8613,3852,282——————
Income Taxes193493436——————
Consolidated Net Income3,6672,8861,854——————
Net Income From Continuing Operations3,6682,8921,846——————
Net Income3,6672,8861,854——————
EPS (Recurring)2.481.961.26——————
EPS (Basic, Before Extraordinaries)2.481.961.26——————
EPS (Diluted)2.461.941.25——————
EBITDA5,8035,1023,938——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio18.5749.1571.46——————
Price To Sales Ratio3.227.037.85——————
Gross Margin71.1669.0161.31——————
Operating Margin21.4619.7815.73——————
Net Margin17.4714.3811.07——————
Shares Outstanding1,4781,4801,472——————
Market Capitalization67,530141,118131,479——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$118.12$96.49$74.86$53.23$31.60● Close Price0.00M3.76M7.52M11.28M15.04MUSD Trades VolumeOctNovDec2026FebMarAprMayJunJulAugSepOct
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
O'Connor Padraig AndrewEVP, Global OperationsSep 02 '26Option Exercise0.001,17108,459Sep 03
Morano Susan EDirectorAug 25 '26Buy49.222,040100,40813,784Aug 26
Habiger David CDirectorAug 05 '26Buy47.592,10099,93717,160Aug 07
Habiger David CDirectorAug 04 '26Buy48.591406,80215,060Aug 05
Mahoney Michael FChairman, President & CEOAug 03 '26Buy48.33186,2409,001,4081,590,024Aug 05
Habiger David CDirectorAug 03 '26Buy48.071,04250,08414,920Aug 05
LUDWIG EDWARD JDirectorJul 31 '26Buy45.485,000227,40030,359Aug 03
Monson JonathanEVP and CFOJul 01 '26Option Exercise0.002,087040,073Jul 02
Habiger David CDirectorMay 20 '26Buy55.922,250125,81913,878May 21
Pegus CherylDirectorMay 20 '26Buy56.491,77099,9871,770May 21
LUDWIG EDWARD JDirectorMay 20 '26Buy56.683,580202,91425,359May 21
Habiger David CDirectorMay 19 '26Buy56.952,200125,27911,628May 21
O'Connor Padraig AndrewEVP, Global OperationsMay 02 '26Option Exercise0.001,80207,896May 04
Butcher Arthur CEVP& Grp Pres, MedSurg & APACMay 02 '26Option Exercise0.002,102057,894May 04
Woodworth EmilySVP, Global Controller and CAOMar 01 '26Option Exercise0.0083803,231Mar 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.